Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB-ABBS Cause Intentional product use issue? 273 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 273 reports of Intentional product use issue have been filed in association with RITUXIMAB-ABBS. This represents 6.3% of all adverse event reports for RITUXIMAB-ABBS.

273
Reports of Intentional product use issue with RITUXIMAB-ABBS
6.3%
of all RITUXIMAB-ABBS reports
77
Deaths
124
Hospitalizations

How Dangerous Is Intentional product use issue From RITUXIMAB-ABBS?

Of the 273 reports, 77 (28.2%) resulted in death, 124 (45.4%) required hospitalization, and 73 (26.7%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB-ABBS. However, 273 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB-ABBS Cause?

Off label use (2,167) Dyspnoea (208) Pain (205) Rheumatoid arthritis (202) Intentional dose omission (196) Fatigue (195) Drug ineffective (186) Hypertension (183) Infusion related reaction (183) Rash (183)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which RITUXIMAB-ABBS Alternatives Have Lower Intentional product use issue Risk?

RITUXIMAB-ABBS vs RITUXIMAB-ARRX RITUXIMAB-ABBS vs RITUXIMAB-PVVR RITUXIMAB-ABBS vs RIVAROXABAN RITUXIMAB-ABBS vs RIVASTIGMINE RITUXIMAB-ABBS vs RIVOTRIL

Related Pages

RITUXIMAB-ABBS Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue RITUXIMAB-ABBS Demographics